Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity

Ernest Yorke

Department of Medicine & Therapeutics, University of Ghana Medical School, Accra, Ghana.

ABSTRACT: Deranged liver enzymes due to hyperthyroidism rather than intrinsic liver pathology are not uncommon. The reported prevalence of liver biochemical abnormalities in patients with untreated thyrotoxicosis varies widely ranging from 15% to 76%. The suggested causes of liver dysfunction include direct hepatocyte injury, co-morbid heart failure, associated autoimmune conditions (especially in the setting of Graves’ Disease), preexisting liver disease and drugs including antithyroid medications. Although, some patients may have a pattern of mild liver injury, about 1% to 2% can have fulminant hepatitis. Liver enzymes can return to normalcy in as many as 77% to 83% of patients once the initiations of thionamides are started in a timely fashion, which can help forestall complications and prevent or minimize multi-organ dysfunction. Clinicians should maintain a high index of suspicion for underlying hyperthyroidism in patients presenting with unexplained liver dysfunction or unexplained jaundice.

KEYWORDS: Hyperthyroidism, liver dysfunction, liver enzymes

Introduction

Hyperthyroidism impacts multiple systems of the body such as the nervous, cardiovascular and gastrointestinal systems, with the liver being an important organ affected in the latter. Hyperthyroidism disproportionately affects women rather than men (5:1) and appears to be common among smokers. The overall incidence of hyperthyroidism is estimated to be about 0.05% to 1.3% with a predominant number being subclinical, this figure rises to between 4% and 5% among older women.

Aside other abnormalities, liver biochemical dysfunctions are found in between 15% and 79% of untreated hyperthyroidism patients with some suffering from severe liver damage of failure and impaired synthetic function. The prevalence of abnormal liver function tests with respect to alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (BIL), and γ-glutamyltransferase (GGT) among the hyperthyroid patients were 33%, 23%, 44%, 12%, and 24% respectively. The two biologically active thyroid hormones are found in between 15% and 79% of untreated hyperthyroidism patients with some suffering from severe liver damage of failure and impaired synthetic function. The liver requires adequate amounts of thyroid hormones to execute its metabolic functions optimally. These aids to maintain the serum free thyroid hormones within narrow limits yet ensure immediate and continuous availability to tissues. It is the serum-free T4 and T3 concentrations that determine the hormones biological activity.

Putative Mechanisms for Liver Dysfunction in Hyperthyroidism

Several direct and indirect mechanisms have been suggested as the cause of liver dysfunction in hyperthyroidism. Summarily, these include direct liver toxicity from prolonged exposure to excessive thyroid hormones and hepatocyte anoxia with
Free-radical damage as a result of the hypermetabolic state, liver cell degeneration from accelerated liver glycogen and protein decomposition, autoimmune-related liver injury, congestive hepatopathy (necrosis) from concomitant thyrotoxic heart failure, previous underlying liver disease and antithyroid medication-related liver toxicity and injury, refer Figure 1.

The pattern of liver dysfunction associated with hyperthyroidism vary. In situations without heart failure and underlying autoimmune causes, elevated aspartate amino transferase, and alanine aminotransferase (transaminitis) results from tissue ischemia and infarction of the hepatocytes. This is as a result of the increase in metabolic activity which increases oxygen demand by the liver. T3 causes apoptosis through a mitochondrion-dependent pathway. Typical histological findings include fatty infiltration of the hepatocytes, nuclear irregularity, hyperchromatism in hepatocytes and vacuolization of the cytoplasm. Cholestatic pattern is commoner than synthetic liver dysfunction, and some may present with severe jaundice as the main presentation. Rises in ALP and GGT are seen about 64% and up to 62% of thyrotoxicosis cases respectively. In situations without heart failure and underlying autoimmune causes, elevated aspartate amino transferase, and alanine aminotransferase (transaminitis) results from tissue ischemia and infarction of the hepatocytes. This is as a result of the increase in metabolic activity which increases oxygen demand by the liver. T3 causes apoptosis through a mitochondrion-dependent pathway. Typical histological findings include fatty infiltration of the hepatocytes, nuclear irregularity, hyperchromatism in hepatocytes and vacuolization of the cytoplasm. Cholestatic pattern is commoner than synthetic liver dysfunction, and some may present with severe jaundice as the main presentation. Rises in ALP and GGT are seen about 64% and up to 62% of thyrotoxicosis cases respectively. In situations without heart failure and underlying autoimmune causes, elevated aspartate amino transferase, and alanine aminotransferase (transaminitis) results from tissue ischemia and infarction of the hepatocytes. This is as a result of the increase in metabolic activity which increases oxygen demand by the liver. T3 causes apoptosis through a mitochondrion-dependent pathway. Typical histological findings include fatty infiltration of the hepatocytes, nuclear irregularity, hyperchromatism in hepatocytes and vacuolization of the cytoplasm. Cholestatic pattern is commoner than synthetic liver dysfunction, and some may present with severe jaundice as the main presentation. Rises in ALP and GGT are seen about 64% and up to 62% of thyrotoxicosis cases respectively.

Congestive heart failure may occur as a complication of hyperthyroidism (thyrotoxic heart failure) or as a preexisting condition. Whilst sinus tachycardia, atrial fibrillations are common manifestations, frank heart failure is uncommon without underlying pre-existing heart condition. In the series by Wafa et al only two patients with severe hepatic dysfunction had global heart failure. Heart failure usually results in mild abnormalities in liver dysfunction, however, acute congestion may lead to marked increases in aminotransferases and bilirubin similar to values associated with viral and toxic hepatitis. In a recent publication involving 2 patients with Graves’ disease, we found out that the liver dysfunction was a predominantly cholestatic pattern rather than transaminitis in the patient with thyrotoxic heart failure, whilst the second patient without heart failure had equivalent derangements in cholestasis and transaminitis. Generally, it is observed that patients with hyperthyroidism and heart failure exhibit more severe liver dysfunction (deep jaundice, hepatomegaly, ascites and coagulopathy than those without heart failure.

Graves’ disease can occur concurrently with other autoimmune conditions in about 10% of cases; common among these are primary biliary cirrhosis (PBC), autoimmune cholangiopathy (AIC) or autoimmune hepatitis. These autoimmune conditions usually have positive antinuclear antibody (ANA) and high ALP; AIC and some PBC cases are negative for antimitochondrial antibody (AMA).

It is often difficult to decide if the cause of hepatic dysfunction is due to antithyroid medications (thionamides) particularly if liver functions tests (LFTs) were not assessed before commencement of medications. It is estimated that the incidence of antithyroid associated hepatic dysfunction is between 0.1% and 0.2%; and risk factors for hepatic injury include older age and higher doses of antithyroid medications. In severe cases of liver dysfunction, the offending drugs should be withdrawn and consideration given to the use cholestyramine to improve cholestatic symptoms, whilst the underlying hyperthyroidism is definitively treated with radioiodine therapy or surgery.

**Predictors of Liver Dysfunction and Recovery**

So far, studies have not demonstrated a correlation between abnormal liver biochemical tests and thyroid hormone levels. Generally, there is normalization of liver dysfunction as thyroid hormone improves. Li et al found out that among Graves’ disease patients, higher thyroid hormone of free thyroxine (FT4) >70.5 pmol/L with the heart rate above 90 beats per minute, the risk of hepatic function injury increases. Another study also found that hepatic abnormalities were greater in a cohort of 19 patients with hyperthyroidism and chronic heart failure (CHF).

Timely initiation of antithyroid medications lead to improvement in liver dysfunction; particularly when biochemical euthyroidism is attained. In a recent systematic review and meta-analysis, following the initiation of antithyroid medications and attainment of euthyroidism, there was normalization abnormalities in ALT, AST, ALP, BIL, and GGT in 83%, 87%, 53%, 50%, and 70% respectively.

**Conclusion**

Hepatic dysfunction associated with thyrotoxicosis is common finding in clinical practice. Whilst the exact mechanisms are unknown, both direct and indirect causes are involved. The
challenge is sometimes to establish the definitive factor causing liver injury in a particular patient. Examination of liver function in the setting of hyperthyroidism is important to identify any abnormalities; timely initiation of antithyroid medication generally results in improvement.

Author Contributions

EY conceived the study and its design, data search, analysis, drafted and produced the final manuscript.

ORCID iD

Ernest Yorke ♦ https://orcid.org/0000-0003-4257-7492

Data Accessibility/ Availability

The data used to support the findings of this study are available from the corresponding author upon request.

REFERENCES

1. Mansourian AR. Liver functional behavior during thyrotoxicosis: a review. J Biol Sci. 2013;13:665-678.
2. Soldin OP, Goughenour BE, Gilbert SZ, Landy HJ, Soldin SJ. Thyroid hormone levels associated with active and passive cigarette smoking. Thyroid. 2009;19:817-823.
3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
4. Scappaticcio L, Maiorino MI, Esposito K, Bellastella G. Neutropenia in patients with hyperthyroidism: systematic review and meta-analysis. Clin Endocrinol. 2021;94:473-483.
5. Ashkar FS, Miller R, Smaok Won 3rd, Gilson AJ. Liver disease in hyperthyroidism. South Med J. 1971;64:462-465.
6. Opoku-Akomeampong NAAS, Agyei-Nkansah A, Yorke E. Liver dysfunction associated with hyperthyroidism: lessons from 2 case reports. Clin Case Rep. 2021;9:e04067.
7. Scappaticcio L, Longo M, Maiorino MI, et al. Abnormal liver blood tests in patients with hyperthyroidism: systematic review and meta-analysis. Thyroid. 2021;31:884-894.
8. Kopp P. Thyroid hormone synthesis. In: Braverman LE, ed. Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text. 10th ed. Lippincott Williams & Wilkins; 2012:48-74.
9. Engler D, Burger AG. The deiodination of the iodothyronines and of their derivatives in man. Endocr Rev. 1984;5:151-184.
10. Fagiuoli S, Van Thiel DH. The liver in endocrine disorders. In: Rustgi VK, Van Thiel DH, eds. The Liver in Systemic Disease. Raven Press; 1993:285-287.
11. de Campos Mazo DF, de Vasconcelos GB, Pereira MA, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol. 2011;6:9-17.
12. Kubota S, Amino N, Matsumoto Y, et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves’ disease and painless thyroiditis. Thyroid. 2008;18:283-287.
13. Khechichian S, Fong T-L. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol. 2017;7:337.
14. Benoistman W, Kacem FH, Gargouri I, Elleuch M, Mnif F, Abid M. Hyperthyroidism and hepatic dysfunction: the impact of congestive heart failure. Paper presented at: 21st European Congress of Endocrinology, Lyon, France, May 18–21. Endocrine Abstracts; 2019; 1213.
15. Doran GR. Serum enzyme disturbances in thyrotoxicosis and myxoedema. J R Soc Med. 1978;71:189-194.
16. Azzi F. Gamma-Glutamyl transpeptidase levels in thyroid disease. Arch Intern Med. 1982;142:79-81.
17. Bal C, Chawla M. Hyperthyroidism and jaundice. Indian J Nucl Med. 2010;25:131-134.
18. Wafa B, Faten H, Mouna E, Fatma M, Mohamed A. Hyperthyroidism and hepatic dysfunction: report of 17 cases. JGH Open. 2020;4:876-879.
19. Duran GR. Serum enzyme disturbances in thyrotoxicosis and myxoedema. J R Soc Med. 1978;71:189-194.
20. Benoistman W, Kacem FH, Gargouri I, Elleuch M, Mnif F, Abid M. Hyperthyroidism and hepatic dysfunction: the impact of congestive heart failure. Paper presented at: 21st European Congress of Endocrinology, Lyon, France, May 18–21. Endocrine Abstracts; 2019; 1213.
21. Wafa B, Faten H, Mouna E, Fatma M, Mohamed A. Hyperthyroidism and hepatic dysfunction: report of 17 cases. JGH Open. 2020;4:876-879.
22. Elias RM, Dean DS, Barsness GW. Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience. Int J Clin Exp Gastroenterol. 2012;5:1-6.
23. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123:183.e1-183.e189.
24. Cooper DS. Anithyroid drugs. New Engl J Med. 2005;352:905-917.
25. Wang R, Tan J, Zhang G, Zheng W, Li C. Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment. Medicine. 2017;96:6035.
26. Akande TO, Balogun WO. A report of three cases of jaundice with thyrotoxicosis. Afr Health Sci. 2013;13:851-856.
27. Li C, Tan J, Zhang G, et al. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study. Horm Metab Res. 2015;47:209-213.